View Future GrowthClarivate 過去の業績過去 基準チェック /06Clarivateは18.4%の年平均成長率で業績を伸ばしているが、Professional Services業界はgrowingで8.8%毎年増加している。売上は成長しており、年平均4.7%の割合である。主要情報18.44%収益成長率18.98%EPS成長率Professional Services 業界の成長14.49%収益成長率4.67%株主資本利益率-7.36%ネット・マージン-13.84%前回の決算情報30 Jun 2026最近の業績更新Reported Earnings • Jul 30Second quarter 2026 earnings released: US$0.42 loss per share (vs US$0.11 loss in 2Q 2025)Second quarter 2026 results: US$0.42 loss per share (further deteriorated from US$0.11 loss in 2Q 2025). Revenue: US$587.3m (down 5.5% from 2Q 2025). Net loss: US$268.6m (loss widened 273% from 2Q 2025). Revenue is expected to decline by 5.4% p.a. on average during the next 3 years, while revenues in the Professional Services industry in Europe are expected to grow by 5.6%. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.お知らせ • Jul 10Clarivate Plc to Report Q2, 2026 Results on Jul 29, 2026Clarivate Plc announced that they will report Q2, 2026 results Pre-Market on Jul 29, 2026お知らせ • Apr 15Clarivate Plc to Report Q1, 2026 Results on Apr 29, 2026Clarivate Plc announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026お知らせ • Jan 28Clarivate Plc to Report Q4, 2025 Results on Feb 24, 2026Clarivate Plc announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026お知らせ • Oct 06Clarivate Plc to Report Q3, 2025 Results on Oct 29, 2025Clarivate Plc announced that they will report Q3, 2025 results Pre-Market on Oct 29, 2025お知らせ • Jul 08Clarivate Plc to Report Q2, 2025 Results on Jul 30, 2025Clarivate Plc announced that they will report Q2, 2025 results Pre-Market on Jul 30, 2025すべての更新を表示Recent updatesRecent Insider Transactions • Aug 11Independent Director recently bought €1.4m worth of stockOn the 7th of August, Kenneth Cornick bought around 900k shares on-market at roughly €1.61 per share. This transaction amounted to 78% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €3.9m more in shares than they have sold in the last 12 months.お知らせ • Aug 06Clarivate Expands Agentic Ai Capabilities Across Cortellis PortfolioClarivate Plc announced the expansion of agentic AI capabilities across the Cortellis portfolio, helping life sciences R&D teams accelerate discovery, strengthen safety assessment and make faster, more informed portfolio decisions. By embedding AI directly within existing workflows, the new capabilities enable researchers to reduce manual effort, navigate complexity and focus on higher-value scientific and strategic decisions. The Cortellis suite of solutions combines trusted life sciences data, expert curation and AI to help R&D, portfolio strategy, business development and regulatory professionals act on intelligence across the drug development lifecycle. The latest AI capabilities help life sciences teams accelerate work across discovery, safety and portfolio strategy. New capabilities within Cortellis Drug Discovery Intelligence enable researchers to engage with complex drug intelligence through natural language, rapidly evaluate therapeutic landscapes, compare compounds and targets and prioritize promising opportunities. By reducing time spent gathering and synthesizing information, teams can focus more of their expertise on advancing the most compelling paths forward. Enhanced capabilities within OFF-X introduce multi-agent intelligence that helps safety teams surface potential liabilities earlier, synthesize evidence more efficiently and support more proactive risk evaluation across development and post-market activities. These capabilities strengthen safety assessment while improving consistency and productivity. New agentic workflows within Cortellis Competitive Intelligence help strategy and business development teams monitor evolving markets, assess competitive dynamics and evaluate external growth opportunities by transforming weeks of manual analysis into actionable intelligence delivered in hours. Powered by proprietary data, expert curation and embedded AI, Cortellis helps life sciences teams connect evidence, streamline complex workflows and move from insight to action with greater speed and confidence.Reported Earnings • Jul 30Second quarter 2026 earnings released: US$0.42 loss per share (vs US$0.11 loss in 2Q 2025)Second quarter 2026 results: US$0.42 loss per share (further deteriorated from US$0.11 loss in 2Q 2025). Revenue: US$587.3m (down 5.5% from 2Q 2025). Net loss: US$268.6m (loss widened 273% from 2Q 2025). Revenue is expected to decline by 5.4% p.a. on average during the next 3 years, while revenues in the Professional Services industry in Europe are expected to grow by 5.6%. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.お知らせ • Jul 30+ 1 more updateClarivate Plc Announces CFO ChangesClarivate Plc announced the appointment of Michael Easton, age 53, as Chief Financial Officer, effective August 8, 2026. On July 24, 2026, Jonathan Collins, the Executive Vice President & Chief Financial Officer of Clarivate Plc (the Company") resigned from his position, effective August 7, 2026. Mr. Collins' departure is not as a result of any disagreement with the Company, its management, its Board of Directors, or the Company's independent auditors. Mr. Easton has more than 25 years of experience in finance and accounting. Mr. Easton has been at the Company since June 2022, currently serves as Senior Vice President, Finance & Chief Accounting Officer at the Company, and has been responsible for the Company’s global controllership, financial reporting, treasury and corporate FP&A functions. Between October 2012 and May 2022, Mr. Easton served as Senior Vice President, Financial Planning and Analysis at IHS Inc., where he oversaw corporate FP&A, as well as the product and regional finance teams across the Americas, Europe and Asia, and as Senior Vice President and Chief Accounting Officer at IHS Markit Ltd., where he led global accounting, financial reporting and finance operations functions following the merger between IHS Inc. and Markit Ltd. in July 2016. Mr. Easton spent more than 14 years with Ernst & Young, where he held positions of increasing responsibility in assurance services. Mr. Easton holds bachelor’s and master's degrees in accounting from Brigham Young University and is a Certified Public Accountant. As CFO, Mr. Easton will focus on advancing Clarivate's strategic priorities, including accelerating growth, improving profitability, strengthening free cash flow generation and maintaining disciplined capital allocation.Breakeven Date Change • Jul 29The 2 analysts covering Clarivate previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 74% per year to 2027. The company is expected to make a profit of US$23.5m in 2028. Average annual earnings growth of 131% is required to achieve expected profit on schedule.お知らせ • Jul 14Clarivate Selected by Abes to Modernize French National Academic Library SystemClarivate Plc announced that the Bibliographic Agency for Higher Education (Abes) has selected the company to modernize France's national academic library system, under a multi-year agreement. Abes supports higher education and research institutions across France with a documentation system including shared library data and services. It also operates Sudoc, a national shared cataloging system for print and electronic resources, containing over 15 million bibliographic records, with a network of 3,000 libraries. The new Clarivate solution will bring together library services, resource sharing and AI-powered discovery in one cloud-based platform. It will replace legacy systems used for the national union catalog and the interlibrary loan service used by thousands of academic libraries and institutions nationwide. Using Clarivate's Alma, Rapido and Primo solutions, Abes will modernize how libraries manage resources, share materials and help users discover content. The move will also support a transition to a linked-data model aligned with international standards. The Abes official announcement says: "The choice of Clarivate's software suite was first and foremost a pragmatic decision, dictated by the unavoidable reality of the global document computing market. In a constrained economic context, this award guarantees exceptional value for money for the agency and its networks. It makes it possible to significantly improve the quality of the service offered while maintaining a measured cost, thus meeting the requirement of exemplarity and efficiency of the State in the consumption of public funds." The new agreement supplements existing Clarivate support for over 70 academic institutions with Alma and Primo at the institutional and regional level in France.お知らせ • Jul 10Clarivate Plc to Report Q2, 2026 Results on Jul 29, 2026Clarivate Plc announced that they will report Q2, 2026 results Pre-Market on Jul 29, 2026New Risk • Jul 07New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$137m Forecast net loss in 2 years: US$4.1m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$4.1m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change).お知らせ • Jul 06Clarivate plc Reaffirms Earnings Guidance for the Full Year Ending December 31, 2026Clarivate Plc reaffirmed earnings guidance for the full year ending December 31, 2026. For the year, the company expects revenues in the range of $2.30 billion to $2.42 billion.お知らせ • Jun 29+ 4 more updatesClarivate Plc(NYSE:CLVT) dropped from Russell Midcap IndexClarivate Plc(NYSE:CLVT) dropped from Russell Midcap Indexお知らせ • Jun 09Clarivate plc Announces President of Intellectual Property Segment ChangesClarivate Plc announced that Simon Webster had been appointed President of the Company's Intellectual Property segment effective June 10, 2026, succeeding Maroun S. Mourad, who will be pursuing other opportunities, effective June 9, 2026. Following such date, Mr. Mourad will remain employed by the Company in a non-executive advisory role until September 30, 2026. Mr. Mourad will ensure a smooth transition and depart from Clarivate at the end of September. Mr. Webster is a proven executive with more than two decades of experience helping global businesses scale, innovate and deliver greater value to customers. He most recently served as Group CEO of Vistra, a corporate and fund solutions company based in Singapore, from 2022 to 2025, leading the company through a $6.5 billion merger with Tricor. Prior to Vistra, Mr. Webster held a number of senior roles at CPA Global, a global leader in IP software and technology-enabled services, since 2000, most recently serving as CEO from 2015 to 2021. During his tenure at CPA Global, he helped build the company into one of the industry's leading IP platforms, before its sale to Clarivate in 2020. Earlier in his career, Mr. Webster held roles of increasing responsibility across the U.K. financial services sector. He is a Chartered Management Accountant, having been elected a Fellow of the Chartered Institute of Management Accountants in 2005.お知らせ • May 29Clarivate Plc Introduces IPOne Unified IP Intelligence PlatformClarivate Plc announced IPOne, a unified platform that combines purpose-built AI agents and trusted proprietary data to power intellectual property (IP) research and workflows across enterprise environments. IPOne is being developed in collaboration with leading corporate IP teams and law firms to support real-world IP workflows. Through the new unified IP intelligence platform, law firms and corporate IP teams will leverage Clarivate AI agents to seamlessly connect trusted proprietary IP data, including Derwent patent, Darts-ip litigation and CompuMark trademark and industrial design data, to support IP workflows and decision-making. The IPOne solution is being specifically developed for high-value use cases such as discovery, clearance, prioritization, monitoring, analysis and decision support across the IP lifecycle. The IPOne platform includes Model Context Protocols (MCPs) to enable secure integration with enterprise AI tools. MCPs, an open standard that allows AI tools to securely connect to external data sources, tools and services, integrate authoritative intelligence into enterprise LLM platforms. As a result, organizations can embed trusted IP intelligence directly into their systems to enhance decision-making while preserving transparency and control.お知らせ • May 08Clarivate plc Launches Web of Science Research IntelligenceClarivate Plc announced the global launch of Web of Science Research Intelligence, an AI-native research intelligence platform designed to support decision-making across funding, strategy and impact for research institutions. Developed in close partnership with the global research community and shaped by more than 50 development partners and early adopters across 20 countries, Web of Science Research Intelligence is now available to institutions worldwide. The platform brings together trusted, curated Clarivate data with responsible academic AI to help research offices, library teams and researchers secure funding, strengthen collaboration, inform strategy and demonstrate real-world impact. Web of Science Research Intelligence unifies fragmented data and embeds responsible academic AI directly into research workflows, enabling faster analysis, more confident decisions and clearer communication of research value. Its multidimensional Societal Impact Framework supports institutions in moving beyond traditional metrics to understand and demonstrate how research contributes to policy, practice and wider social outcomes. AI-guided workflows within the platform extend advanced analytical capabilities beyond specialist teams and enable more users across the institution to contribute to research planning and strategy. The platform connects curated Clarivate data across the research lifecycle – including publications, patents, funding, policy documents and clinical trials – to create a single, reliable foundation for decision-making. Built on publisher-neutral Web of Science Core Collection data, long recognized as the global standard for bibliometric analysis, Web of Science Research Intelligence delivers the quality, consistency and traceability required for high-stakes institutional decisions. Institutions can use Web of Science Research Intelligence to: Discover and track funding opportunities aligned to research priorities; Identify experts and build stronger collaboration networks; Explore emerging research areas and connect them to funding, expertise and impact; Create and share transparent, organization-level reporting on research performance; Analyze and communicate societal impact of research using multidimensional indicators and clear narratives. Unlike general-purpose AI tools that rely on broad, unverified sources, Web of Science Research Intelligence generates insights grounded in curated, authoritative data, with transparency into how analyses are created. This supports explainable, traceable and reliable insights – a critical requirement for institutional research decision-making. Web of Science Research Intelligence has been shaped through ongoing collaboration with research institutions worldwide to ensure alignment with real-world workflows and adoption across diverse teams. Its global network of development partners continues to inform the platform's evolution through practical institutional use cases. Developed in partnership with the research community, Web of Science Research Intelligence is an AI-native platform that helps institutions and researchers increase funding, optimize strategy, and demonstrate impact. Built on trusted, unified Clarivate data from Web of Science Core Collection, Derwent Innovations Index, Cortellis Clinical Trials Intelligence, and Pivot-RP, it provides a holistic view of research performance, supported by responsible AI and a transparent Societal Impact Framework developed by the Institute for Scientific Information.お知らせ • Apr 30+ 1 more updateClarivate plc Reaffirms Earnings Guidance for the Full Year Ending December 31, 2026Clarivate Plc reaffirmed earnings guidance for the full year ending December 31, 2026. For the year, the company expects revenues in the range of $2.30 billion to $2.42 billion. Net loss to be $189 million to $124 million. Net loss per share to be in the range of $0.29 to $0.19.お知らせ • Apr 15Clarivate Plc to Report Q1, 2026 Results on Apr 29, 2026Clarivate Plc announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026お知らせ • Feb 24+ 1 more updateClarivate plc Provides Earnings Guidance for the Full Year Ending December 31, 2026Clarivate Plc provided earnings guidance for the full year ending December 31, 2026. For the year, the company expects revenues in the range of $2.30 billion to $2.42 billion. Net loss to be in the range of $189 million to $124 million. Net loss margin to be in the range of 8.2% to 5.1%. Net loss per share to be in the range of $0.29 to $0.19.お知らせ • Jan 28Clarivate Plc to Report Q4, 2025 Results on Feb 24, 2026Clarivate Plc announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026お知らせ • Oct 29Clarivate plc Revises Earnings Guidance for the Full Year 2025Clarivate Plc revised earnings guidance for the full year 2025. For the year, the company now expects revenues in the range of $2.42 Billion to $2.45 Billion compared to previous guidance of $2.28 Billion to $2.40 Billion.お知らせ • Oct 06Clarivate Plc to Report Q3, 2025 Results on Oct 29, 2025Clarivate Plc announced that they will report Q3, 2025 results Pre-Market on Oct 29, 2025お知らせ • Aug 14Clarivate Launches AI-Powered Regulatory Assistant Within Cortellis Suite to Boost Productivity and Ease Regulatory BurdenClarivate Plc announced the beta launch of its AI-powered Regulatory Assistant within Cortellis Regulatory Intelligence. This new capability is designed to help regulatory professionals navigate complex and evolving global requirements with greater ease, speed and confidence. Informed by customer input and tested with industry partners, the beta version of the Regulatory Assistant is built to meet the real-world needs of regulatory professionals across biopharma, medtech and research organizations. The Regulatory Assistant will be launched to all Cortellis Regulatory Intelligence users in September with additional capabilities designed to further enhance usability, personalization and decision support. Features within the Beta version of Cortellis Regulatory Intelligence AI Assistant include: Conversational AI with referenced answers: Users can ask regulatory questions naturally and get precise,ited responses, saving hours of manual work. The AI-powered Assistant, guided by domain expertise, understands regulatory nuances to provide customers with accurate answers. Your conversations, always within reach: Users can pick up right where they left off with chat history, resulting in more relevant, personalized responses. Multilingual by design: Search and interact in preferred languages for a seamless, tailored experience. With market-leading intelligence solutions, transformative data technologies and trusted AI, Clarivate equips customers with the insight and foresight they need across every stage of the product lifecycle, from early discovery through commercialization and beyond. In line with this commitment, the new AI-powered Regulatory Assistant brings the Clarivate mission to life by helping customers navigate complexity, accelerate decision-making and shape the future of healthcare. As regulatory professionals face mounting pressure to keep pace with global changes, interpret complex requirements, and ensure compliance, the Regulatory Assistant streamlines access to trusted intelligence, enabling faster, more confident decisions. Built on the same proven Clarivate AI platform that powers Clarivate solutions, including Web of Science, and trusted by hundreds of organizations, it combines powerful technology with 30+ years of regulatory expertise relied on by top pharma and global agencies.お知らせ • Jul 31Clarivate Plc Announces Departure of Valeria Alberola from the Board, Effective December 31, 2025Clarivate Plc announced that Valeria Alberola notified the Company of her intention to resign from the Board of Directors of the Company, effective as of December 31, 2025. Ms. Alberola confirmed that her decision to resign is due to a change in her primary employment and not as a result of any disagreement between her and the Company, its management, the Board of Directors, or any committee thereof.お知らせ • Jul 30+ 1 more updateClarivate Plc Announces Executive ChangesClarivate Plc announced that Maroun S. Mourad will join the company as President of the Intellectual Property (IP) segment, effective September 8, 2025. Maroun most recently served as President of the Claims Solutions division of Verisk Analytics Inc. He succeeds Gordon Samson, who will retire at the end of 2025 after a high-impact career in the IP industry, spending five years as the Chief Operating Officer at CPA Global, before joining the Clarivate executive team, most recently as the President of the IP segment. As a data analytics and software executive, Maroun has profitably grown businesses in the U.S., U.K., Europe, and emerging markets since 1998. Most recently, Maroun led the integrated suite of products and services for the Verisk Analytics Claims Solutions division. He was responsible for the product portfolio, services, and acquisitions that deliver value to clients across the insurance policy lifecycle worldwide. His focus on team building, customer-centricity, and delivering quality results has driven business transformations in established, start-up, and turnaround environments. Maroun holds a BA in political science and a JD, both from the University of California, Berkeley.お知らせ • Jul 08Clarivate Plc to Report Q2, 2025 Results on Jul 30, 2025Clarivate Plc announced that they will report Q2, 2025 results Pre-Market on Jul 30, 2025お知らせ • Jun 19TRADEMARK Promotes Greg Villeneuve to Executive Producer and Vice President of OperationsTRADEMARK announced the promotion of Greg Villeneuve to Executive Producer and Vice President of Operations. A key member of the Trademark team since 2016, Greg has played an instrumental role in producing some of the company’s most ambitious, design-forward events for industry-defining brands, including Adobe, Webflow, and Lucasfilm. In his expanded role, Greg will oversee Trademark’s end-to-end production operations, driving excellence across project delivery, budget stewardship, resource planning, and operational systems. His leadership will continue to elevate TRADEMARK’s ability to execute world-class events that push creative boundaries while maintaining sound operations. Over nearly a decade with Trademark, Greg has led production for high-profile experiential events, bringing artistry and precision to complex brand environments. Behind the scenes, he has also spearheaded the evolution of Trademark’s internal systems, developing scalable workflows for budgeting, scheduling, and production tracking that have improved efficiency across the organization and ensured excellent results for TRADEMARK clients. Greg holds a Bachelor of Arts from Washington University in St. Louis, MO. He has demonstrated professional capabilities in event budgeting, high-end production, event and venue contracts, vendor management, and creative ideation and development. With this promotion, Greg steps into a critical leadership role as TRADEMARK expands its capabilities and partnerships across experiential, virtual, and hybrid productions for leading brands across technology, gaming, biotech, travel, and entertainment.お知らせ • May 15Clarivate Enhances Off-X with Pathway Maps to Accelerate Target Safety AssessmentsClarivate Plc announced the incorporation of Pathway Maps in OFF-X, a cutting-edge translational safety intelligence solution. With over 30% of drug development failures attributed to safety issues1, preclinical and translational research teams face increasing pressure to identify potential liabilities earlier in the target selection process. Pathway Maps provide powerful visual tools that offer deeper insights into the biological mechanisms underlying diseases and target interactions, streamlining target safety assessments and enabling faster, data-driven decisions. Traditional safety data collection is often fragmented and time-consuming, creating delays in critical go/no-go decisions. With the addition of Pathway Maps to OFF-X, researchers can now explore disease-specific visualizations of key signaling pathways and molecular processes--uniquely overlaid with curated, multi-source safety data. This integration enables users to quickly pinpoint potential safety liabilities across upstream or downstream targets, adding biological context to risk assessment. By bringing together visual disease biology and comprehensive safety intelligence in one platform, OFF-X addresses a critical industry gap--empowering teams to make faster, more confident decisions across the drug development lifecycle. With this release, OFF-X reaffirms its unique position as a platform that integrates proprietary physiological and disease pathway visualizations with curated safety data from diverse sources. This integration streamlines data access and enhances risk evaluation, providing researchers with the confidence to make more informed decisions and refine mitigation strategies. Designed to support researchers throughout the drug development lifecycle--from early discovery to post-marketing surveillance-- OFF-X offers a unified resource for translational safety intelligence. In the drug discovery and preclinical space, the combination OFF-X and Cortellis Drug Discovery Intelligence provides the most powerful approach for researchers to cover both efficacy and safety.お知らせ • May 13Clarivate Plc, Annual General Meeting, May 14, 2026Clarivate Plc, Annual General Meeting, May 14, 2026.お知らせ • Apr 30Clarivate plc Reaffirms Earnings Guidance for the Year Ending December 31, 2025Clarivate Plc reaffirmed earnings guidance for the year Ending December 31, 2025. For the year, the company expects Revenues to be $2.28 Billion to $2.40 Billion.お知らせ • Apr 23Clarivate Plc Launches DRG Commercial Analytics 360 Enabling Medtech Companies to Advance Commercial Strategy and ExecutionClarivate Plc announced the launch of DRG Commercial Analytics 360—a solution designed to empower medtech companies with advanced insights to drive commercial performance. As the demand for precise, analytics-driven strategies grows, medtech companies require deeper visibility into customer activity, affiliations, practice behavior and caseloads. DRG Commercial Analytics 360 equips commercial teams with the insights needed to navigate the complex U.S. provider landscape, engage key stakeholder, and improve both patient access and business outcomes. Tailored for the medtech sector, the platform combines the robust search capabilities of Procedure Finder with the extensive Clarivate provider and affiliations network. It delivers real-world, data-driven intelligence, enabling medtech companies to optimize strategic planning, field sales performance and market execution. To meet the evolving demands of complex targeting in medtech, DRG Commercial Analytics 360 delivers a suite of capabilities that enable smarter, data-driven decisions across the commercial organization: Actionable Intelligence: Integrated healthcare provider data and analytics offer clear, tailored insights into who is treating targeted patients, their network affiliations, and where procedures are performed—across hospitals, mbulatory surgery centers, and other care settings. Accurate, De-duplicated Market Segments: By categorizing procedures by type and eliminating code-level duplication, the platform ensures a reliable, detailed view of procedure volume and flow across the U.S. market. 360° Market Visibility: Modularized claims and code groupings are aligned with precise market definitions to support accurate market sizing and informed resource allocation. Expert-Led Data Intelligence: Backed by in-house medtech, medical coding, and U.S. healthcare expertise, Clarivate data scientists apply tailored extrapolation methodologies to surface nuanced insights across market segments. The Clarivate medtech team partners with medical device companies and distributors to fully harness the value of DRG Commercial Analytics 360—whether building national strategy or optimizing field sales planning.お知らせ • Apr 02Clarivate Plc to Report Q1, 2025 Results on Apr 29, 2025Clarivate Plc announced that they will report Q1, 2025 results Pre-Market on Apr 29, 2025お知らせ • Mar 18Clarivate Plc, Annual General Meeting, May 07, 2025Clarivate Plc, Annual General Meeting, May 07, 2025. Location: 70 st. mary axe, london ec3a 8be, United Kingdomお知らせ • Mar 01Clarivate plc Announces Retirement of Michael J. Angelakis from Board of Directors, Effective May 7, 2025On February 25, 2025, Michael J. Angelakis notified Clarivate Plc of his decision to retire from the Board of Directors of the Company (the “Board”), effective upon the re-election of members of the Board at the Company’s 2025 Annual General Meeting of Shareholders to be held on May 7, 2025, and withdrew from consideration for re-election as a member of the Board.お知らせ • Jan 22Clarivate Plc to Report Q4, 2024 Results on Feb 19, 2025Clarivate Plc announced that they will report Q4, 2024 results Pre-Market on Feb 19, 2025お知らせ • Jan 14Clarivate plc Launches Drg Fusion - A New Life Sciences Analytics Product Powered by Real-World DataClarivate Plc announced the launch of DRG Fusion, an innovative platform to support commercial analytics in life sciences. Powered by integrated real-world data and built by clinical and data science experts, Fusion provides biopharma and medtech organizations with the tools to understand and act in varied disease and competitive landscapes -- eliminating the complexities of raw data management. Fusion addresses the critical needs of biopharma and medtech commercial, sales and marketing teams by offering modular data analytics products aligned to functional team needs. Pre-built modules provide users with configurable dashboards to support patient journey analysis, commercial targeting, market access optimization and patient segmentation. Fusion streamlines the data management and querying process for life sciences organizations by simplifying complex data analysis with ready-made, informative visuals and tables accelerating commercial decisions.お知らせ • Dec 16Clarivate Plc (NYSE:CLVT) announces an Equity Buyback for $500 million worth of its shares.Clarivate Plc (NYSE:CLVT) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its ordinary shares. The company expects to fund the purchases with cash on hand. The program will run through December 31, 2026.お知らせ • Dec 14Clarivate plc Announces Retirement of Richard Roedel from the Board of Directors, Effective January 1, 2025On July 23, 2024, Richard Roedel notified Clarivate Plc of his retirement from the Board of Directors of the Company, effective as of December 31, 2024. On December 10, 2024, Mr. Roedel amended the effective date of his retirement from the Board of Directors of the Company to January 1, 2025.Breakeven Date Change • Nov 08Forecast breakeven date pushed back to 2026The 8 analysts covering Clarivate previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$131.0m in 2026. Average annual earnings growth of 92% is required to achieve expected profit on schedule.お知らせ • Oct 29Silverchair Science + Communications, Inc. signed a definitive agreement to acquire ScholarOne, Inc. from Clarivate Plc (NYSE:CLVT).Silverchair Science + Communications, Inc. signed a definitive agreement to acquire ScholarOne, Inc. from Clarivate Plc (NYSE:CLVT) on October 28, 2024. The acquisition is expected to close within the fourth quarter of 2024 subject to the satisfaction of customary closing conditions.お知らせ • Oct 16Clarivate Plc to Report Q3, 2024 Results on Nov 06, 2024Clarivate Plc announced that they will report Q3, 2024 results Pre-Market on Nov 06, 2024お知らせ • Sep 04Clarivate Launches Generative AI-Powered Web of Science Research AssistantClarivate Plc released the Web of Science™ Research Assistant. The new generative AI-powered tool helps researchers find key papers faster, handle complex research tasks and visualize connections. The chat interface combined with the Web of Science knowledge graph allows researchers to get more out of their interactions with 120 years of trusted publication and citation data in the Web of Science Core Collection™. The Web of Science Research Assistant features include: Flexible search for documents – Users can conduct natural language searches in several languages. The tool delivers overviews that consider more than 120 years of research and reveals connections between concepts and papers in a field of study. Guided prompts and tasks – The tool suggests ways users can enhance their research tasks, following context-specific prompts to expand or refine the scope of discovery. Guided tasks including 'Understand a topic', 'Literature review' or 'Find a journal' help researchers focus on exactly what they need. Unique data visualizations – Users can explore trend graphs, topic maps and co-citation networks that show different angles on a topic and guide them deeper into their research. The tool was developed in collaboration with librarians and researchers worldwide and entered beta testing in December 2023. Development partners help ensure that the generative AI-powered assistant meets rigorous standards for quality, accuracy and privacy. The Web of Science Research Assistant team will continue to work with the community to gather feedback and guidance for future enhancements.お知らせ • Aug 20Clarivate plc Appoints Melanie Margolin as Chief Administrative and Legal OfficerClarivate Plc has appointed Melanie Margolin to the expanded role of Chief Administrative and Legal Officer. She joined the company as Executive Vice President and Chief Legal Officer in September 2023. Ms. Margolin successfully leverages her experience as a seasoned executive to advance key strategic programs at Clarivate. She has a proven track record of establishing strong controls for complex organizations through business-first legal advice and a sustained focus on people-centric leadership. In her expanded role, Ms. Margolin will oversee human resources, facilities, communications and brand functions in addition to global legal affairs, risk, sustainability, privacy and compliance. Melanie Margolin is a legal expert and business leader with more than 25 years of experience overseeing legal, risk mitigation, corporate governance and compliance for global publicly listed companies. Prior to joining Clarivate, Ms. Margolin served as Chief Legal Officer for Thumbtack, a venture-backed leading local services marketplace. Ms. Margolin also previously served as Senior Vice President, General Counsel and Corporate Secretary for Wabash National Inc., an industrial manufacturing and transportation company, and as Deputy General Counsel at Cummins Inc., a global power manufacturer and distribution business. Ms. Margolin holds a bachelor's degree in speech communication from University of Illinois, a juris doctor from DePaul University College of Law and is a graduate of the Executive Finance Program at Harvard Business School.New Risk • Aug 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (7.1% increase in shares outstanding).Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.46 loss per share (vs US$0.21 loss in 2Q 2023)Second quarter 2024 results: US$0.46 loss per share (further deteriorated from US$0.21 loss in 2Q 2023). Revenue: US$650.3m (down 2.8% from 2Q 2023). Net loss: US$316.8m (loss widened 124% from 2Q 2023). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 06+ 3 more updatesClarivate plc Announces Directorate ChangesClarivate Plc announced that the Board has appointed Matti Shem Tov, former CEO of ProQuest, as the Company's next CEO, effective August 9, 2024. Mr. Shem Tov will also join the Company's Board of Directors. Jonathan Gear, Chief Executive Officer, will step down as CEO and as a member of the Board at that time, and will transition into a non-executive role until November 1, 2024. Matti Shem Tov has over 30 years of global leadership experience with deep expertise in software, data, and analytics, as well as in driving innovation and growth. From June 2022 until March 2024, Mr. Shem Tov served as an operating partner at Lone View Capital, a private equity firm. Prior to that, Mr. Shem Tov served as Chief Executive Officer of ProQuest LLC ("ProQuest"), a provider of global data, analytics and software, to academic, research and national institutions, from September 2017 to June 2022, including for a period following Clarivate's acquisition of ProQuest in December 2021. From 2003 until 2017, Mr. Shem Tov served as President and Chief Executive Officer of Ex Libris Ltd., leading the company to become a prominent developer of cloud-based software solutions for academic, national and research institutions worldwide. Prior to joining Ex Libris, Mr. Shem Tov served as President of Surecomp Limited, a global software company specializing in commercial banking solutions, after serving in various leadership roles across the company. Mr. Shem Tov received his Bachelor of Arts and his Master of Business Administration from Bar-Ilan University.お知らせ • Jul 24Clarivate plc Announces Board and Committee ChangesClarivate Plc announced that Richard Roedel will retire from the Board of Directors for health reasons, effective December 31, 2024. The Board expects Valeria Alberola, a member of the Board since May 2021, and a member of its Audit and Finance Committees, to succeed Mr. Roedel as Chair of the Audit Committee. Ms. Alberola brings over 25 years of global experience in corporate finance, investment banking, sustainable investments, operations and strategic management consulting. From January 2019 until March 2024, Ms. Alberola served as Chief Executive Officer of Zoma Holdings, LLC following her tenure as its Chief Operating Officer from 2017 to December 2018. Previously she was the Chief Financial Officer of Bridge Education Group Inc., a global education company, and a partner at Q Advisors LLC, an investment banking firm, advising on M&A and debt and equity financings for technology and telecommunications clients. Ms. Alberola received a B.S. in Economics and Business Administration from the Pontificia Universidad Católica de Chile and an M.B.A. from the Kellogg School of Management at Northwestern University, where she was a Fulbright scholar.お知らせ • Jul 22Clarivate Plc (NYSE:CLVT) acquired Rowan TELS Corp.Clarivate Plc (NYSE:CLVT) acquired Rowan TELS Corp. on July 22, 2024. Clarivate Plc (NYSE:CLVT) completed the acquisition of Rowan TELS Corp. on July 22, 2024.お知らせ • Jul 16Clarivate Plc to Report Q2, 2024 Results on Aug 06, 2024Clarivate Plc announced that they will report Q2, 2024 results Pre-Market on Aug 06, 2024お知らせ • Jun 24Clarivate Plc Launches IP Collaboration HubClarivate Plc launched the IP Collaboration Hub™ at the 2024 Clarivate Ignite conference held in San Diego, U.S. The new solution integrates with Clarivate IP management systems (IPMS) to provide a central hub for collaborating with local agents worldwide. The IP Collaboration Hub enables users to save time and reduce risks in the IP filing and prosecution process by providing a portal for instructors and local agents to collaborate and exchange information, while automatically docketing everything in the IPMS. This portal addresses a critical issue in the IP industry - over-reliance on email for communication - which introduces risk into the process. The Hub automates and standardizes communication management between law firms, corporations and their local agents. The new solution enables users to manage their entire foreign filing and prosecution process for patents and trademarks from a single, structured mechanism for automated docketing fully integrated with their IPMS. The structured process eliminates human errors or missing documents when sending instructions, avoiding mistakes that could lead to loss of IP rights.お知らせ • May 09Clarivate Plc Reaffirms Earnings Guidance for the Fiscal Year 2024Clarivate Plc reaffirmed earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of $2.57 billion to $2.67 billion.Reported Earnings • May 08First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.037 profit in 1Q 2023)First quarter 2024 results: US$0.14 loss per share (down from US$0.037 profit in 1Q 2023). Revenue: US$621.2m (down 1.3% from 1Q 2023). Net loss: US$93.8m (down 480% from profit in 1Q 2023). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.お知らせ • May 03Clarivate Plc Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory SuccessClarivate Plc announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions. CMC activities account for nearly 18% of the entire R&D budget, emphasizing the importance of optimization and validation. Cortellis CMC Intelligence for post-approval variations enables clients to compare requirements across 64 countries, reducing tracking time and increasing submission rates with organized, timely, and accurate information. With its new module covering both pre- and post-approval documents, Cortellis CMC Intelligence offers comprehensive lifecycle information for drugs and biologics. Serving as a single-platform solution for CMC requirements, it effectively reduces tracking time and unnecessary costs. About Cortellis CMC Intelligence Cortellis CMC Intelligence curates and tracks official CMC regulations and local practices for more than 135+ countries, territories and organizations for small molecules and 64 countries, territories and regions for biologics, with pre-and post-approval module coverage. Robust data is available for 25+ product and regulatory-related filters based on eCTD structure, including 6K+ source documents and over 2K links to Cortellis Regulatory Intelligence, providing access to expanded detail and in-depth summaries from experts in local regulatory practices, paired with reference source documents, to offer a complete picture. The addition of a new post-approval module now makes a comprehensive CMC solution with complete lifecycle information for drugs and biologics to increase submission rates and avoid costly delays.お知らせ • Apr 16Clarivate Plc to Report Q1, 2024 Results on May 08, 2024Clarivate Plc announced that they will report Q1, 2024 results Pre-Market on May 08, 2024お知らせ • Mar 13Astorg Reportedly Considers Sale of AnaquaPrivate equity firm Astorg Asset Management S A.R.L. is considering a sale of its U.S.-based intellectual property software firm Anaqua, Inc., four people familiar with the matter told Reuters, with two of them saying the company could be worth as much as $3 billion. Astorg is in the process of appointing financial advisers to gauge buyer interest in Anaqua, which offers software that manages patents, trademarks and contracts for law firms and corporations, the sources said. The process is in the early stages and Astorg is expected to proceed with an auction in the second half of the year, the people said, speaking on condition of anonymity. Astorg declined to comment. Anaqua did not immediately return requests for comment. Anaqua's competitors include French software firm QUESTEL SAS, backed by IK Partners and Eurazeo, and British-American business Clarivate Plc (NYSE:CLVT), formerly the intellectual property and science division of Thomson Reuters, according to one of the sources. Questel is among those considering a possible bid for the business, a fifth person familiar with the process said. Questel did not immediately return requests for comment. IK Partners and Eurazeo declined to comment.お知らせ • Mar 05Clarivate Plc, Annual General Meeting, May 07, 2024Clarivate Plc, Annual General Meeting, May 07, 2024. Agenda: To consider election to the Board of Directors.お知らせ • Feb 29+ 1 more updateClarivate plc Provides Earnings Guidance for the Fiscal Year 2024Clarivate Plc provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of $2,570 million to $2,670 million.Reported Earnings • Feb 28Full year 2023 earnings released: US$1.47 loss per share (vs US$5.97 loss in FY 2022)Full year 2023 results: US$1.47 loss per share (improved from US$5.97 loss in FY 2022). Revenue: US$2.63b (down 1.2% from FY 2022). Net loss: US$986.6m (loss narrowed 76% from FY 2022). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.お知らせ • Jan 25Clarivate Plc to Report Q4, 2023 Results on Feb 27, 2024Clarivate Plc announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Feb 27, 2024Valuation Update With 7 Day Price Move • Dec 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €8.65, the stock trades at a trailing P/E ratio of 34.3x. Average forward P/E is 16x in the Professional Services industry in Germany. Total loss to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.04 per share.お知らせ • Dec 19Clarivate plc Announces Launch of New Special Report Series, Electrophysiology Mapping and Ablation Devices Market InsightsClarivate Plc announced the launch of a new special report series, Electrophysiology Mapping and Ablation Devices Market Insights. The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific. Findings show pulsed-field ablation (PFA) is poised to revolutionize the treatment paradigm. PFA has emerged as a breakthrough technology for the treatment of atrial fibrillation, attracting significant investment from several companies dedicated to its development. This innovative technique has produced favorable clinical outcomes compared to existing technologies and has the potential to see immediate widespread adoption following FDA approval. While both Boston Scientific and Medtronic have IDE trials for their PFA devices, Medtronic's PulseSelect PFA system received FDA approval on December 13, 2023 and Boston Scientific's FARAPULSE is expected to closely follow. There has already been a swift adoption of PFA, spurred by the approval of FARAPULSE in Europe in 2021 and its subsequent approval in Australia in 2023. This year, the global PFA market value is estimated to be $232 million with the potential to grow to $2.9 billion by the year 2028. The Electrophysiology Mappingand Ablation Devices Market Insights reports provide in-depth data and analysis of clinical practice, patient journey, and competing therapies, allowing medical device companies and physicians to make more informed and strategic decisions. The new reports highlight revised forecasts in the space for four geographies, covering: Electrophysiology Mapping & Ablation Devices - Market Insights - United States. The US EP mapping and ablation device market, which includes PFA among other technologies, is projected to experience strong growth through 2028 and is anticipated to reach a total market value of $7.2 billion by that year, driven strongly by PFA uptake. The COVID-19 pandemic had a significant impact on certain EP ablation procedures in 2020, followed by a period of recovery. Growth in market revenues will be driven by increasing ablation procedure volumes and the uptake of premium-priced devices. Innovations in this space will lead to improved outcomes and procedure growth. Electrophysiology Mapping, Ablation Devices - Market Ins insights - Asia Pacific: Although the global COVID-19 pandemic negatively impacted the Asia Pacific EP mapping and ablation devicemarket in 2020, the market has shown strong recovery and will resume pre-pandemic growth trends in the nearterm. Going forward, the Asia Pacific EP mapping and Ablation device market will expand rapidly, supported by rising AF treatment volumes, an expanding patient pool, improving access to healthcare, and the emergence of newer, premium-priced devices. Although cost constraints and a challenging reimbursement environment will hinder the pace of market expansion to some extent, the total market value is projected to reach $3.6 billion by the year 2028".Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €7.45, the stock trades at a trailing P/E ratio of 28.3x. Average forward P/E is 15x in the Professional Services industry in Europe. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.96 per share.Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.01 loss per share (vs US$6.58 loss in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share (improved from US$6.58 loss in 3Q 2022). Revenue: US$647.2m (up 1.8% from 3Q 2022). Net loss: US$6.60m (loss narrowed 100% from 3Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 30 percentage points per year, which is a significant difference in performance.お知らせ • Nov 08Clarivate plc Provides Revenue Guidance for the Full Year 2023Clarivate Plc provided revenue guidance for the full year 2023. For the period,the company expects revenues to be in the range of $2.60 billion to $2.67 billion.Breakeven Date Change • Nov 08The 10 analysts covering Clarivate previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 88% per year to 2024. The company is expected to make a profit of US$39.8m in 2025.お知らせ • Oct 18Impactive Capital Engages in Discussions with Clarivate PlcOn October 16, 2023, Impactive Capital LP announced that it has, from time to time, engaged in, and intends to continue to engage in, discussions with members of management and the board of directors of Clarivate Plc, other shareholders, industry analysts, existing or potential strategic partners or competitors and other third parties regarding a variety of matters relating to the Company, which may include, among other things, the Company’s business, operations and expenses, strategic alternatives and direction, management, Board and management composition, environmental, social and governance considerations, and capital structure and allocation.お知らせ • Oct 17Clarivate Plc to Report Q3, 2023 Results on Nov 07, 2023Clarivate Plc announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023New Risk • Oct 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$4.2b Forecast net loss in 2 years: US$9.2m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.4% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$9.2m net loss in 2 years).New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Sep 27Clarivate Plc (NYSE:CLVT) acquired Alethea.Clarivate Plc (NYSE:CLVT) acquired Alethea on September 26, 2023. Eran Segal, co-founder and CEO of Pangea and his team will join Clarivate.Clarivate Plc (NYSE:CLVT) completed the acquisition of Alethea on September 26, 2023.お知らせ • Sep 26Clarivate Plc Establishes Academia & Government Innovation IncubatorClarivate Plc announced it has established an Academia & Government Innovation Incubator. This will further accelerate its strategy to drive innovation, utilize artificial intelligence and introduce novel solutions for its academic users and customers. The Incubator's first program focuses on realizing better learning outcomes and student success through the acquisition of Alethea, an AI-powered students' content engagement platform created by Pangea. Alethea facilitates meaningful engagement with academic texts, class readings, and assignments through personalized and adaptive guidance. It provides faculty and librarians with the insights they need to analyze students' reading engagement and rapidly adapt their teaching.New Risk • Aug 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Breakeven Date Change • Aug 04Forecast breakeven date pushed back to 2024The 8 analysts covering Clarivate previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 100% to 2023. The company is expected to make a profit of US$6.64m in 2024. Average annual earnings growth of 171% is required to achieve expected profit on schedule.お知らせ • Aug 04+ 1 more updateClarivate plc Updates Earnings Guidance for the Year 2023Clarivate Plc updated earnings guidance for the year 2023. For the year, the company expects revenue to be $2.60 Billion to $2.67 Billion compared to previous guidance of $2.63 Billion to $2.73 Billion.Reported Earnings • Aug 03Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.065 profit in 2Q 2022)Second quarter 2023 results: US$0.21 loss per share (down from US$0.065 profit in 2Q 2022). Revenue: US$668.8m (down 2.6% from 2Q 2022). Net loss: US$141.7m (down 424% from profit in 2Q 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.お知らせ • Jul 08Clarivate Plc to Report Q2, 2023 Results on Aug 03, 2023Clarivate Plc announced that they will report Q2, 2023 results at 9:30 AM, US Eastern Standard Time on Aug 03, 2023お知らせ • Jun 28Clarivate Plc, Annual General Meeting, Jul 27, 2023Clarivate Plc, Annual General Meeting, Jul 27, 2023, at 08:00 Eastern Daylight. Location: THE GROVE, Chandler’s Cross, Hertfordshire, WD3 4TG Heretfordshire United Kingdom Agenda: To approve repurchase of ordinary shares in open-market transactions on the terms described in further detail herein (the Open-Market Share Repurchase Proposal"); and to transact such other business as may properly come before the General Meeting.お知らせ • May 13Clarivate Plc Elects Saurabh Saha as DirectorClarivate Plc held its 2023 Annual General Meeting of Shareholders on May 4, 2023, elected Saurabh Saha as director.Breakeven Date Change • May 10Forecast breakeven date moved forward to 2023The 9 analysts covering Clarivate previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$49.6m in 2023. Earnings growth of 107% is required to achieve expected profit on schedule.お知らせ • May 10Clarivate plc Provides Earnings Guidance for the Year 2023Clarivate Plc provided earnings guidance for the year 2023. For the year, the company expects revenues in the range of $2.63 billion to $2.73 billion, Organic Revenue Growth in the range of 2.75% to 3.75%.Reported Earnings • May 09First quarter 2023 earnings released: EPS: US$0.037 (vs US$0.074 in 1Q 2022)First quarter 2023 results: EPS: US$0.037 (down from US$0.074 in 1Q 2022). Revenue: US$629.1m (down 5.0% from 1Q 2022). Net income: US$24.7m (down 51% from 1Q 2022). Profit margin: 3.9% (down from 7.7% in 1Q 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.Breakeven Date Change • Mar 02No longer forecast to breakevenThe 7 analysts covering Clarivate no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$90.4m in 2024. New consensus forecast suggests the company will make a loss of US$65.5m in 2024.お知らせ • Feb 08Clarivate Plc to Report Q4, 2022 Results on Mar 01, 2023Clarivate Plc announced that they will report Q4, 2022 results Pre-Market on Mar 01, 2023Recent Insider Transactions • Nov 18Chief Product Officer recently sold €1.0m worth of stockOn the 15th of November, Gordon Samson sold around 100k shares on-market at roughly €10.09 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.4m more than they bought in the last 12 months.Breakeven Date Change • Nov 16Forecast breakeven date pushed back to 2024The 8 analysts covering Clarivate previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 49% per year to 2023. The company is expected to make a profit of US$113.6m in 2024. Average annual earnings growth of 121% is required to achieve expected profit on schedule.収支内訳Clarivate の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:16A 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Jun 262,413-334707031 Mar 262,447-137707031 Dec 252,455-201709030 Sep 252,501-396710030 Jun 252,500-433710031 Mar 252,529-678714031 Dec 242,557-668728030 Sep 242,577-1,339732030 Jun 242,602-1,280732031 Mar 242,621-1,105739031 Dec 232,629-987740030 Sep 232,620181735030 Jun 232,609-4,247735031 Mar 232,627-4,062729031 Dec 222,660-4,036730030 Sep 222,545-4,470734030 Jun 222,352-30709031 Mar 222,111-205702031 Dec 211,877-312643030 Sep 211,772-195635030 Jun 211,614-383622031 Mar 211,442-277546031 Dec 201,254-351545030 Sep 201,053-469516030 Jun 201,012-277490031 Mar 20981-329513031 Dec 19974-259475030 Sep 19965-170419030 Jun 19964-235410031 Mar 19965-224379031 Dec 18968-242413031 Dec 17918-2643610質の高い収益: 16Aは現在利益が出ていません。利益率の向上: 16Aは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 16Aは利益を出していないが、過去 5 年間で年間18.4%の割合で損失を削減してきた。成長の加速: 16Aの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 16Aは利益が出ていないため、過去 1 年間の収益成長をProfessional Services業界 ( 2.4% ) と比較することは困難です。株主資本利益率高いROE: 16Aは現在利益が出ていないため、自己資本利益率 ( -7.36% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YCommercial-services 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/17 23:19終値2026/08/17 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Clarivate Plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Manav PatnaikBarclaysHeather BalskyBofA Global ResearchZachary CumminsB. Riley Securities, Inc.10 その他のアナリストを表示
Reported Earnings • Jul 30Second quarter 2026 earnings released: US$0.42 loss per share (vs US$0.11 loss in 2Q 2025)Second quarter 2026 results: US$0.42 loss per share (further deteriorated from US$0.11 loss in 2Q 2025). Revenue: US$587.3m (down 5.5% from 2Q 2025). Net loss: US$268.6m (loss widened 273% from 2Q 2025). Revenue is expected to decline by 5.4% p.a. on average during the next 3 years, while revenues in the Professional Services industry in Europe are expected to grow by 5.6%. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
お知らせ • Jul 10Clarivate Plc to Report Q2, 2026 Results on Jul 29, 2026Clarivate Plc announced that they will report Q2, 2026 results Pre-Market on Jul 29, 2026
お知らせ • Apr 15Clarivate Plc to Report Q1, 2026 Results on Apr 29, 2026Clarivate Plc announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026
お知らせ • Jan 28Clarivate Plc to Report Q4, 2025 Results on Feb 24, 2026Clarivate Plc announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026
お知らせ • Oct 06Clarivate Plc to Report Q3, 2025 Results on Oct 29, 2025Clarivate Plc announced that they will report Q3, 2025 results Pre-Market on Oct 29, 2025
お知らせ • Jul 08Clarivate Plc to Report Q2, 2025 Results on Jul 30, 2025Clarivate Plc announced that they will report Q2, 2025 results Pre-Market on Jul 30, 2025
Recent Insider Transactions • Aug 11Independent Director recently bought €1.4m worth of stockOn the 7th of August, Kenneth Cornick bought around 900k shares on-market at roughly €1.61 per share. This transaction amounted to 78% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €3.9m more in shares than they have sold in the last 12 months.
お知らせ • Aug 06Clarivate Expands Agentic Ai Capabilities Across Cortellis PortfolioClarivate Plc announced the expansion of agentic AI capabilities across the Cortellis portfolio, helping life sciences R&D teams accelerate discovery, strengthen safety assessment and make faster, more informed portfolio decisions. By embedding AI directly within existing workflows, the new capabilities enable researchers to reduce manual effort, navigate complexity and focus on higher-value scientific and strategic decisions. The Cortellis suite of solutions combines trusted life sciences data, expert curation and AI to help R&D, portfolio strategy, business development and regulatory professionals act on intelligence across the drug development lifecycle. The latest AI capabilities help life sciences teams accelerate work across discovery, safety and portfolio strategy. New capabilities within Cortellis Drug Discovery Intelligence enable researchers to engage with complex drug intelligence through natural language, rapidly evaluate therapeutic landscapes, compare compounds and targets and prioritize promising opportunities. By reducing time spent gathering and synthesizing information, teams can focus more of their expertise on advancing the most compelling paths forward. Enhanced capabilities within OFF-X introduce multi-agent intelligence that helps safety teams surface potential liabilities earlier, synthesize evidence more efficiently and support more proactive risk evaluation across development and post-market activities. These capabilities strengthen safety assessment while improving consistency and productivity. New agentic workflows within Cortellis Competitive Intelligence help strategy and business development teams monitor evolving markets, assess competitive dynamics and evaluate external growth opportunities by transforming weeks of manual analysis into actionable intelligence delivered in hours. Powered by proprietary data, expert curation and embedded AI, Cortellis helps life sciences teams connect evidence, streamline complex workflows and move from insight to action with greater speed and confidence.
Reported Earnings • Jul 30Second quarter 2026 earnings released: US$0.42 loss per share (vs US$0.11 loss in 2Q 2025)Second quarter 2026 results: US$0.42 loss per share (further deteriorated from US$0.11 loss in 2Q 2025). Revenue: US$587.3m (down 5.5% from 2Q 2025). Net loss: US$268.6m (loss widened 273% from 2Q 2025). Revenue is expected to decline by 5.4% p.a. on average during the next 3 years, while revenues in the Professional Services industry in Europe are expected to grow by 5.6%. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
お知らせ • Jul 30+ 1 more updateClarivate Plc Announces CFO ChangesClarivate Plc announced the appointment of Michael Easton, age 53, as Chief Financial Officer, effective August 8, 2026. On July 24, 2026, Jonathan Collins, the Executive Vice President & Chief Financial Officer of Clarivate Plc (the Company") resigned from his position, effective August 7, 2026. Mr. Collins' departure is not as a result of any disagreement with the Company, its management, its Board of Directors, or the Company's independent auditors. Mr. Easton has more than 25 years of experience in finance and accounting. Mr. Easton has been at the Company since June 2022, currently serves as Senior Vice President, Finance & Chief Accounting Officer at the Company, and has been responsible for the Company’s global controllership, financial reporting, treasury and corporate FP&A functions. Between October 2012 and May 2022, Mr. Easton served as Senior Vice President, Financial Planning and Analysis at IHS Inc., where he oversaw corporate FP&A, as well as the product and regional finance teams across the Americas, Europe and Asia, and as Senior Vice President and Chief Accounting Officer at IHS Markit Ltd., where he led global accounting, financial reporting and finance operations functions following the merger between IHS Inc. and Markit Ltd. in July 2016. Mr. Easton spent more than 14 years with Ernst & Young, where he held positions of increasing responsibility in assurance services. Mr. Easton holds bachelor’s and master's degrees in accounting from Brigham Young University and is a Certified Public Accountant. As CFO, Mr. Easton will focus on advancing Clarivate's strategic priorities, including accelerating growth, improving profitability, strengthening free cash flow generation and maintaining disciplined capital allocation.
Breakeven Date Change • Jul 29The 2 analysts covering Clarivate previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 74% per year to 2027. The company is expected to make a profit of US$23.5m in 2028. Average annual earnings growth of 131% is required to achieve expected profit on schedule.
お知らせ • Jul 14Clarivate Selected by Abes to Modernize French National Academic Library SystemClarivate Plc announced that the Bibliographic Agency for Higher Education (Abes) has selected the company to modernize France's national academic library system, under a multi-year agreement. Abes supports higher education and research institutions across France with a documentation system including shared library data and services. It also operates Sudoc, a national shared cataloging system for print and electronic resources, containing over 15 million bibliographic records, with a network of 3,000 libraries. The new Clarivate solution will bring together library services, resource sharing and AI-powered discovery in one cloud-based platform. It will replace legacy systems used for the national union catalog and the interlibrary loan service used by thousands of academic libraries and institutions nationwide. Using Clarivate's Alma, Rapido and Primo solutions, Abes will modernize how libraries manage resources, share materials and help users discover content. The move will also support a transition to a linked-data model aligned with international standards. The Abes official announcement says: "The choice of Clarivate's software suite was first and foremost a pragmatic decision, dictated by the unavoidable reality of the global document computing market. In a constrained economic context, this award guarantees exceptional value for money for the agency and its networks. It makes it possible to significantly improve the quality of the service offered while maintaining a measured cost, thus meeting the requirement of exemplarity and efficiency of the State in the consumption of public funds." The new agreement supplements existing Clarivate support for over 70 academic institutions with Alma and Primo at the institutional and regional level in France.
お知らせ • Jul 10Clarivate Plc to Report Q2, 2026 Results on Jul 29, 2026Clarivate Plc announced that they will report Q2, 2026 results Pre-Market on Jul 29, 2026
New Risk • Jul 07New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$137m Forecast net loss in 2 years: US$4.1m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$4.1m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change).
お知らせ • Jul 06Clarivate plc Reaffirms Earnings Guidance for the Full Year Ending December 31, 2026Clarivate Plc reaffirmed earnings guidance for the full year ending December 31, 2026. For the year, the company expects revenues in the range of $2.30 billion to $2.42 billion.
お知らせ • Jun 29+ 4 more updatesClarivate Plc(NYSE:CLVT) dropped from Russell Midcap IndexClarivate Plc(NYSE:CLVT) dropped from Russell Midcap Index
お知らせ • Jun 09Clarivate plc Announces President of Intellectual Property Segment ChangesClarivate Plc announced that Simon Webster had been appointed President of the Company's Intellectual Property segment effective June 10, 2026, succeeding Maroun S. Mourad, who will be pursuing other opportunities, effective June 9, 2026. Following such date, Mr. Mourad will remain employed by the Company in a non-executive advisory role until September 30, 2026. Mr. Mourad will ensure a smooth transition and depart from Clarivate at the end of September. Mr. Webster is a proven executive with more than two decades of experience helping global businesses scale, innovate and deliver greater value to customers. He most recently served as Group CEO of Vistra, a corporate and fund solutions company based in Singapore, from 2022 to 2025, leading the company through a $6.5 billion merger with Tricor. Prior to Vistra, Mr. Webster held a number of senior roles at CPA Global, a global leader in IP software and technology-enabled services, since 2000, most recently serving as CEO from 2015 to 2021. During his tenure at CPA Global, he helped build the company into one of the industry's leading IP platforms, before its sale to Clarivate in 2020. Earlier in his career, Mr. Webster held roles of increasing responsibility across the U.K. financial services sector. He is a Chartered Management Accountant, having been elected a Fellow of the Chartered Institute of Management Accountants in 2005.
お知らせ • May 29Clarivate Plc Introduces IPOne Unified IP Intelligence PlatformClarivate Plc announced IPOne, a unified platform that combines purpose-built AI agents and trusted proprietary data to power intellectual property (IP) research and workflows across enterprise environments. IPOne is being developed in collaboration with leading corporate IP teams and law firms to support real-world IP workflows. Through the new unified IP intelligence platform, law firms and corporate IP teams will leverage Clarivate AI agents to seamlessly connect trusted proprietary IP data, including Derwent patent, Darts-ip litigation and CompuMark trademark and industrial design data, to support IP workflows and decision-making. The IPOne solution is being specifically developed for high-value use cases such as discovery, clearance, prioritization, monitoring, analysis and decision support across the IP lifecycle. The IPOne platform includes Model Context Protocols (MCPs) to enable secure integration with enterprise AI tools. MCPs, an open standard that allows AI tools to securely connect to external data sources, tools and services, integrate authoritative intelligence into enterprise LLM platforms. As a result, organizations can embed trusted IP intelligence directly into their systems to enhance decision-making while preserving transparency and control.
お知らせ • May 08Clarivate plc Launches Web of Science Research IntelligenceClarivate Plc announced the global launch of Web of Science Research Intelligence, an AI-native research intelligence platform designed to support decision-making across funding, strategy and impact for research institutions. Developed in close partnership with the global research community and shaped by more than 50 development partners and early adopters across 20 countries, Web of Science Research Intelligence is now available to institutions worldwide. The platform brings together trusted, curated Clarivate data with responsible academic AI to help research offices, library teams and researchers secure funding, strengthen collaboration, inform strategy and demonstrate real-world impact. Web of Science Research Intelligence unifies fragmented data and embeds responsible academic AI directly into research workflows, enabling faster analysis, more confident decisions and clearer communication of research value. Its multidimensional Societal Impact Framework supports institutions in moving beyond traditional metrics to understand and demonstrate how research contributes to policy, practice and wider social outcomes. AI-guided workflows within the platform extend advanced analytical capabilities beyond specialist teams and enable more users across the institution to contribute to research planning and strategy. The platform connects curated Clarivate data across the research lifecycle – including publications, patents, funding, policy documents and clinical trials – to create a single, reliable foundation for decision-making. Built on publisher-neutral Web of Science Core Collection data, long recognized as the global standard for bibliometric analysis, Web of Science Research Intelligence delivers the quality, consistency and traceability required for high-stakes institutional decisions. Institutions can use Web of Science Research Intelligence to: Discover and track funding opportunities aligned to research priorities; Identify experts and build stronger collaboration networks; Explore emerging research areas and connect them to funding, expertise and impact; Create and share transparent, organization-level reporting on research performance; Analyze and communicate societal impact of research using multidimensional indicators and clear narratives. Unlike general-purpose AI tools that rely on broad, unverified sources, Web of Science Research Intelligence generates insights grounded in curated, authoritative data, with transparency into how analyses are created. This supports explainable, traceable and reliable insights – a critical requirement for institutional research decision-making. Web of Science Research Intelligence has been shaped through ongoing collaboration with research institutions worldwide to ensure alignment with real-world workflows and adoption across diverse teams. Its global network of development partners continues to inform the platform's evolution through practical institutional use cases. Developed in partnership with the research community, Web of Science Research Intelligence is an AI-native platform that helps institutions and researchers increase funding, optimize strategy, and demonstrate impact. Built on trusted, unified Clarivate data from Web of Science Core Collection, Derwent Innovations Index, Cortellis Clinical Trials Intelligence, and Pivot-RP, it provides a holistic view of research performance, supported by responsible AI and a transparent Societal Impact Framework developed by the Institute for Scientific Information.
お知らせ • Apr 30+ 1 more updateClarivate plc Reaffirms Earnings Guidance for the Full Year Ending December 31, 2026Clarivate Plc reaffirmed earnings guidance for the full year ending December 31, 2026. For the year, the company expects revenues in the range of $2.30 billion to $2.42 billion. Net loss to be $189 million to $124 million. Net loss per share to be in the range of $0.29 to $0.19.
お知らせ • Apr 15Clarivate Plc to Report Q1, 2026 Results on Apr 29, 2026Clarivate Plc announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026
お知らせ • Feb 24+ 1 more updateClarivate plc Provides Earnings Guidance for the Full Year Ending December 31, 2026Clarivate Plc provided earnings guidance for the full year ending December 31, 2026. For the year, the company expects revenues in the range of $2.30 billion to $2.42 billion. Net loss to be in the range of $189 million to $124 million. Net loss margin to be in the range of 8.2% to 5.1%. Net loss per share to be in the range of $0.29 to $0.19.
お知らせ • Jan 28Clarivate Plc to Report Q4, 2025 Results on Feb 24, 2026Clarivate Plc announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026
お知らせ • Oct 29Clarivate plc Revises Earnings Guidance for the Full Year 2025Clarivate Plc revised earnings guidance for the full year 2025. For the year, the company now expects revenues in the range of $2.42 Billion to $2.45 Billion compared to previous guidance of $2.28 Billion to $2.40 Billion.
お知らせ • Oct 06Clarivate Plc to Report Q3, 2025 Results on Oct 29, 2025Clarivate Plc announced that they will report Q3, 2025 results Pre-Market on Oct 29, 2025
お知らせ • Aug 14Clarivate Launches AI-Powered Regulatory Assistant Within Cortellis Suite to Boost Productivity and Ease Regulatory BurdenClarivate Plc announced the beta launch of its AI-powered Regulatory Assistant within Cortellis Regulatory Intelligence. This new capability is designed to help regulatory professionals navigate complex and evolving global requirements with greater ease, speed and confidence. Informed by customer input and tested with industry partners, the beta version of the Regulatory Assistant is built to meet the real-world needs of regulatory professionals across biopharma, medtech and research organizations. The Regulatory Assistant will be launched to all Cortellis Regulatory Intelligence users in September with additional capabilities designed to further enhance usability, personalization and decision support. Features within the Beta version of Cortellis Regulatory Intelligence AI Assistant include: Conversational AI with referenced answers: Users can ask regulatory questions naturally and get precise,ited responses, saving hours of manual work. The AI-powered Assistant, guided by domain expertise, understands regulatory nuances to provide customers with accurate answers. Your conversations, always within reach: Users can pick up right where they left off with chat history, resulting in more relevant, personalized responses. Multilingual by design: Search and interact in preferred languages for a seamless, tailored experience. With market-leading intelligence solutions, transformative data technologies and trusted AI, Clarivate equips customers with the insight and foresight they need across every stage of the product lifecycle, from early discovery through commercialization and beyond. In line with this commitment, the new AI-powered Regulatory Assistant brings the Clarivate mission to life by helping customers navigate complexity, accelerate decision-making and shape the future of healthcare. As regulatory professionals face mounting pressure to keep pace with global changes, interpret complex requirements, and ensure compliance, the Regulatory Assistant streamlines access to trusted intelligence, enabling faster, more confident decisions. Built on the same proven Clarivate AI platform that powers Clarivate solutions, including Web of Science, and trusted by hundreds of organizations, it combines powerful technology with 30+ years of regulatory expertise relied on by top pharma and global agencies.
お知らせ • Jul 31Clarivate Plc Announces Departure of Valeria Alberola from the Board, Effective December 31, 2025Clarivate Plc announced that Valeria Alberola notified the Company of her intention to resign from the Board of Directors of the Company, effective as of December 31, 2025. Ms. Alberola confirmed that her decision to resign is due to a change in her primary employment and not as a result of any disagreement between her and the Company, its management, the Board of Directors, or any committee thereof.
お知らせ • Jul 30+ 1 more updateClarivate Plc Announces Executive ChangesClarivate Plc announced that Maroun S. Mourad will join the company as President of the Intellectual Property (IP) segment, effective September 8, 2025. Maroun most recently served as President of the Claims Solutions division of Verisk Analytics Inc. He succeeds Gordon Samson, who will retire at the end of 2025 after a high-impact career in the IP industry, spending five years as the Chief Operating Officer at CPA Global, before joining the Clarivate executive team, most recently as the President of the IP segment. As a data analytics and software executive, Maroun has profitably grown businesses in the U.S., U.K., Europe, and emerging markets since 1998. Most recently, Maroun led the integrated suite of products and services for the Verisk Analytics Claims Solutions division. He was responsible for the product portfolio, services, and acquisitions that deliver value to clients across the insurance policy lifecycle worldwide. His focus on team building, customer-centricity, and delivering quality results has driven business transformations in established, start-up, and turnaround environments. Maroun holds a BA in political science and a JD, both from the University of California, Berkeley.
お知らせ • Jul 08Clarivate Plc to Report Q2, 2025 Results on Jul 30, 2025Clarivate Plc announced that they will report Q2, 2025 results Pre-Market on Jul 30, 2025
お知らせ • Jun 19TRADEMARK Promotes Greg Villeneuve to Executive Producer and Vice President of OperationsTRADEMARK announced the promotion of Greg Villeneuve to Executive Producer and Vice President of Operations. A key member of the Trademark team since 2016, Greg has played an instrumental role in producing some of the company’s most ambitious, design-forward events for industry-defining brands, including Adobe, Webflow, and Lucasfilm. In his expanded role, Greg will oversee Trademark’s end-to-end production operations, driving excellence across project delivery, budget stewardship, resource planning, and operational systems. His leadership will continue to elevate TRADEMARK’s ability to execute world-class events that push creative boundaries while maintaining sound operations. Over nearly a decade with Trademark, Greg has led production for high-profile experiential events, bringing artistry and precision to complex brand environments. Behind the scenes, he has also spearheaded the evolution of Trademark’s internal systems, developing scalable workflows for budgeting, scheduling, and production tracking that have improved efficiency across the organization and ensured excellent results for TRADEMARK clients. Greg holds a Bachelor of Arts from Washington University in St. Louis, MO. He has demonstrated professional capabilities in event budgeting, high-end production, event and venue contracts, vendor management, and creative ideation and development. With this promotion, Greg steps into a critical leadership role as TRADEMARK expands its capabilities and partnerships across experiential, virtual, and hybrid productions for leading brands across technology, gaming, biotech, travel, and entertainment.
お知らせ • May 15Clarivate Enhances Off-X with Pathway Maps to Accelerate Target Safety AssessmentsClarivate Plc announced the incorporation of Pathway Maps in OFF-X, a cutting-edge translational safety intelligence solution. With over 30% of drug development failures attributed to safety issues1, preclinical and translational research teams face increasing pressure to identify potential liabilities earlier in the target selection process. Pathway Maps provide powerful visual tools that offer deeper insights into the biological mechanisms underlying diseases and target interactions, streamlining target safety assessments and enabling faster, data-driven decisions. Traditional safety data collection is often fragmented and time-consuming, creating delays in critical go/no-go decisions. With the addition of Pathway Maps to OFF-X, researchers can now explore disease-specific visualizations of key signaling pathways and molecular processes--uniquely overlaid with curated, multi-source safety data. This integration enables users to quickly pinpoint potential safety liabilities across upstream or downstream targets, adding biological context to risk assessment. By bringing together visual disease biology and comprehensive safety intelligence in one platform, OFF-X addresses a critical industry gap--empowering teams to make faster, more confident decisions across the drug development lifecycle. With this release, OFF-X reaffirms its unique position as a platform that integrates proprietary physiological and disease pathway visualizations with curated safety data from diverse sources. This integration streamlines data access and enhances risk evaluation, providing researchers with the confidence to make more informed decisions and refine mitigation strategies. Designed to support researchers throughout the drug development lifecycle--from early discovery to post-marketing surveillance-- OFF-X offers a unified resource for translational safety intelligence. In the drug discovery and preclinical space, the combination OFF-X and Cortellis Drug Discovery Intelligence provides the most powerful approach for researchers to cover both efficacy and safety.
お知らせ • May 13Clarivate Plc, Annual General Meeting, May 14, 2026Clarivate Plc, Annual General Meeting, May 14, 2026.
お知らせ • Apr 30Clarivate plc Reaffirms Earnings Guidance for the Year Ending December 31, 2025Clarivate Plc reaffirmed earnings guidance for the year Ending December 31, 2025. For the year, the company expects Revenues to be $2.28 Billion to $2.40 Billion.
お知らせ • Apr 23Clarivate Plc Launches DRG Commercial Analytics 360 Enabling Medtech Companies to Advance Commercial Strategy and ExecutionClarivate Plc announced the launch of DRG Commercial Analytics 360—a solution designed to empower medtech companies with advanced insights to drive commercial performance. As the demand for precise, analytics-driven strategies grows, medtech companies require deeper visibility into customer activity, affiliations, practice behavior and caseloads. DRG Commercial Analytics 360 equips commercial teams with the insights needed to navigate the complex U.S. provider landscape, engage key stakeholder, and improve both patient access and business outcomes. Tailored for the medtech sector, the platform combines the robust search capabilities of Procedure Finder with the extensive Clarivate provider and affiliations network. It delivers real-world, data-driven intelligence, enabling medtech companies to optimize strategic planning, field sales performance and market execution. To meet the evolving demands of complex targeting in medtech, DRG Commercial Analytics 360 delivers a suite of capabilities that enable smarter, data-driven decisions across the commercial organization: Actionable Intelligence: Integrated healthcare provider data and analytics offer clear, tailored insights into who is treating targeted patients, their network affiliations, and where procedures are performed—across hospitals, mbulatory surgery centers, and other care settings. Accurate, De-duplicated Market Segments: By categorizing procedures by type and eliminating code-level duplication, the platform ensures a reliable, detailed view of procedure volume and flow across the U.S. market. 360° Market Visibility: Modularized claims and code groupings are aligned with precise market definitions to support accurate market sizing and informed resource allocation. Expert-Led Data Intelligence: Backed by in-house medtech, medical coding, and U.S. healthcare expertise, Clarivate data scientists apply tailored extrapolation methodologies to surface nuanced insights across market segments. The Clarivate medtech team partners with medical device companies and distributors to fully harness the value of DRG Commercial Analytics 360—whether building national strategy or optimizing field sales planning.
お知らせ • Apr 02Clarivate Plc to Report Q1, 2025 Results on Apr 29, 2025Clarivate Plc announced that they will report Q1, 2025 results Pre-Market on Apr 29, 2025
お知らせ • Mar 18Clarivate Plc, Annual General Meeting, May 07, 2025Clarivate Plc, Annual General Meeting, May 07, 2025. Location: 70 st. mary axe, london ec3a 8be, United Kingdom
お知らせ • Mar 01Clarivate plc Announces Retirement of Michael J. Angelakis from Board of Directors, Effective May 7, 2025On February 25, 2025, Michael J. Angelakis notified Clarivate Plc of his decision to retire from the Board of Directors of the Company (the “Board”), effective upon the re-election of members of the Board at the Company’s 2025 Annual General Meeting of Shareholders to be held on May 7, 2025, and withdrew from consideration for re-election as a member of the Board.
お知らせ • Jan 22Clarivate Plc to Report Q4, 2024 Results on Feb 19, 2025Clarivate Plc announced that they will report Q4, 2024 results Pre-Market on Feb 19, 2025
お知らせ • Jan 14Clarivate plc Launches Drg Fusion - A New Life Sciences Analytics Product Powered by Real-World DataClarivate Plc announced the launch of DRG Fusion, an innovative platform to support commercial analytics in life sciences. Powered by integrated real-world data and built by clinical and data science experts, Fusion provides biopharma and medtech organizations with the tools to understand and act in varied disease and competitive landscapes -- eliminating the complexities of raw data management. Fusion addresses the critical needs of biopharma and medtech commercial, sales and marketing teams by offering modular data analytics products aligned to functional team needs. Pre-built modules provide users with configurable dashboards to support patient journey analysis, commercial targeting, market access optimization and patient segmentation. Fusion streamlines the data management and querying process for life sciences organizations by simplifying complex data analysis with ready-made, informative visuals and tables accelerating commercial decisions.
お知らせ • Dec 16Clarivate Plc (NYSE:CLVT) announces an Equity Buyback for $500 million worth of its shares.Clarivate Plc (NYSE:CLVT) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its ordinary shares. The company expects to fund the purchases with cash on hand. The program will run through December 31, 2026.
お知らせ • Dec 14Clarivate plc Announces Retirement of Richard Roedel from the Board of Directors, Effective January 1, 2025On July 23, 2024, Richard Roedel notified Clarivate Plc of his retirement from the Board of Directors of the Company, effective as of December 31, 2024. On December 10, 2024, Mr. Roedel amended the effective date of his retirement from the Board of Directors of the Company to January 1, 2025.
Breakeven Date Change • Nov 08Forecast breakeven date pushed back to 2026The 8 analysts covering Clarivate previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$131.0m in 2026. Average annual earnings growth of 92% is required to achieve expected profit on schedule.
お知らせ • Oct 29Silverchair Science + Communications, Inc. signed a definitive agreement to acquire ScholarOne, Inc. from Clarivate Plc (NYSE:CLVT).Silverchair Science + Communications, Inc. signed a definitive agreement to acquire ScholarOne, Inc. from Clarivate Plc (NYSE:CLVT) on October 28, 2024. The acquisition is expected to close within the fourth quarter of 2024 subject to the satisfaction of customary closing conditions.
お知らせ • Oct 16Clarivate Plc to Report Q3, 2024 Results on Nov 06, 2024Clarivate Plc announced that they will report Q3, 2024 results Pre-Market on Nov 06, 2024
お知らせ • Sep 04Clarivate Launches Generative AI-Powered Web of Science Research AssistantClarivate Plc released the Web of Science™ Research Assistant. The new generative AI-powered tool helps researchers find key papers faster, handle complex research tasks and visualize connections. The chat interface combined with the Web of Science knowledge graph allows researchers to get more out of their interactions with 120 years of trusted publication and citation data in the Web of Science Core Collection™. The Web of Science Research Assistant features include: Flexible search for documents – Users can conduct natural language searches in several languages. The tool delivers overviews that consider more than 120 years of research and reveals connections between concepts and papers in a field of study. Guided prompts and tasks – The tool suggests ways users can enhance their research tasks, following context-specific prompts to expand or refine the scope of discovery. Guided tasks including 'Understand a topic', 'Literature review' or 'Find a journal' help researchers focus on exactly what they need. Unique data visualizations – Users can explore trend graphs, topic maps and co-citation networks that show different angles on a topic and guide them deeper into their research. The tool was developed in collaboration with librarians and researchers worldwide and entered beta testing in December 2023. Development partners help ensure that the generative AI-powered assistant meets rigorous standards for quality, accuracy and privacy. The Web of Science Research Assistant team will continue to work with the community to gather feedback and guidance for future enhancements.
お知らせ • Aug 20Clarivate plc Appoints Melanie Margolin as Chief Administrative and Legal OfficerClarivate Plc has appointed Melanie Margolin to the expanded role of Chief Administrative and Legal Officer. She joined the company as Executive Vice President and Chief Legal Officer in September 2023. Ms. Margolin successfully leverages her experience as a seasoned executive to advance key strategic programs at Clarivate. She has a proven track record of establishing strong controls for complex organizations through business-first legal advice and a sustained focus on people-centric leadership. In her expanded role, Ms. Margolin will oversee human resources, facilities, communications and brand functions in addition to global legal affairs, risk, sustainability, privacy and compliance. Melanie Margolin is a legal expert and business leader with more than 25 years of experience overseeing legal, risk mitigation, corporate governance and compliance for global publicly listed companies. Prior to joining Clarivate, Ms. Margolin served as Chief Legal Officer for Thumbtack, a venture-backed leading local services marketplace. Ms. Margolin also previously served as Senior Vice President, General Counsel and Corporate Secretary for Wabash National Inc., an industrial manufacturing and transportation company, and as Deputy General Counsel at Cummins Inc., a global power manufacturer and distribution business. Ms. Margolin holds a bachelor's degree in speech communication from University of Illinois, a juris doctor from DePaul University College of Law and is a graduate of the Executive Finance Program at Harvard Business School.
New Risk • Aug 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (7.1% increase in shares outstanding).
Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.46 loss per share (vs US$0.21 loss in 2Q 2023)Second quarter 2024 results: US$0.46 loss per share (further deteriorated from US$0.21 loss in 2Q 2023). Revenue: US$650.3m (down 2.8% from 2Q 2023). Net loss: US$316.8m (loss widened 124% from 2Q 2023). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 06+ 3 more updatesClarivate plc Announces Directorate ChangesClarivate Plc announced that the Board has appointed Matti Shem Tov, former CEO of ProQuest, as the Company's next CEO, effective August 9, 2024. Mr. Shem Tov will also join the Company's Board of Directors. Jonathan Gear, Chief Executive Officer, will step down as CEO and as a member of the Board at that time, and will transition into a non-executive role until November 1, 2024. Matti Shem Tov has over 30 years of global leadership experience with deep expertise in software, data, and analytics, as well as in driving innovation and growth. From June 2022 until March 2024, Mr. Shem Tov served as an operating partner at Lone View Capital, a private equity firm. Prior to that, Mr. Shem Tov served as Chief Executive Officer of ProQuest LLC ("ProQuest"), a provider of global data, analytics and software, to academic, research and national institutions, from September 2017 to June 2022, including for a period following Clarivate's acquisition of ProQuest in December 2021. From 2003 until 2017, Mr. Shem Tov served as President and Chief Executive Officer of Ex Libris Ltd., leading the company to become a prominent developer of cloud-based software solutions for academic, national and research institutions worldwide. Prior to joining Ex Libris, Mr. Shem Tov served as President of Surecomp Limited, a global software company specializing in commercial banking solutions, after serving in various leadership roles across the company. Mr. Shem Tov received his Bachelor of Arts and his Master of Business Administration from Bar-Ilan University.
お知らせ • Jul 24Clarivate plc Announces Board and Committee ChangesClarivate Plc announced that Richard Roedel will retire from the Board of Directors for health reasons, effective December 31, 2024. The Board expects Valeria Alberola, a member of the Board since May 2021, and a member of its Audit and Finance Committees, to succeed Mr. Roedel as Chair of the Audit Committee. Ms. Alberola brings over 25 years of global experience in corporate finance, investment banking, sustainable investments, operations and strategic management consulting. From January 2019 until March 2024, Ms. Alberola served as Chief Executive Officer of Zoma Holdings, LLC following her tenure as its Chief Operating Officer from 2017 to December 2018. Previously she was the Chief Financial Officer of Bridge Education Group Inc., a global education company, and a partner at Q Advisors LLC, an investment banking firm, advising on M&A and debt and equity financings for technology and telecommunications clients. Ms. Alberola received a B.S. in Economics and Business Administration from the Pontificia Universidad Católica de Chile and an M.B.A. from the Kellogg School of Management at Northwestern University, where she was a Fulbright scholar.
お知らせ • Jul 22Clarivate Plc (NYSE:CLVT) acquired Rowan TELS Corp.Clarivate Plc (NYSE:CLVT) acquired Rowan TELS Corp. on July 22, 2024. Clarivate Plc (NYSE:CLVT) completed the acquisition of Rowan TELS Corp. on July 22, 2024.
お知らせ • Jul 16Clarivate Plc to Report Q2, 2024 Results on Aug 06, 2024Clarivate Plc announced that they will report Q2, 2024 results Pre-Market on Aug 06, 2024
お知らせ • Jun 24Clarivate Plc Launches IP Collaboration HubClarivate Plc launched the IP Collaboration Hub™ at the 2024 Clarivate Ignite conference held in San Diego, U.S. The new solution integrates with Clarivate IP management systems (IPMS) to provide a central hub for collaborating with local agents worldwide. The IP Collaboration Hub enables users to save time and reduce risks in the IP filing and prosecution process by providing a portal for instructors and local agents to collaborate and exchange information, while automatically docketing everything in the IPMS. This portal addresses a critical issue in the IP industry - over-reliance on email for communication - which introduces risk into the process. The Hub automates and standardizes communication management between law firms, corporations and their local agents. The new solution enables users to manage their entire foreign filing and prosecution process for patents and trademarks from a single, structured mechanism for automated docketing fully integrated with their IPMS. The structured process eliminates human errors or missing documents when sending instructions, avoiding mistakes that could lead to loss of IP rights.
お知らせ • May 09Clarivate Plc Reaffirms Earnings Guidance for the Fiscal Year 2024Clarivate Plc reaffirmed earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of $2.57 billion to $2.67 billion.
Reported Earnings • May 08First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.037 profit in 1Q 2023)First quarter 2024 results: US$0.14 loss per share (down from US$0.037 profit in 1Q 2023). Revenue: US$621.2m (down 1.3% from 1Q 2023). Net loss: US$93.8m (down 480% from profit in 1Q 2023). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
お知らせ • May 03Clarivate Plc Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory SuccessClarivate Plc announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions. CMC activities account for nearly 18% of the entire R&D budget, emphasizing the importance of optimization and validation. Cortellis CMC Intelligence for post-approval variations enables clients to compare requirements across 64 countries, reducing tracking time and increasing submission rates with organized, timely, and accurate information. With its new module covering both pre- and post-approval documents, Cortellis CMC Intelligence offers comprehensive lifecycle information for drugs and biologics. Serving as a single-platform solution for CMC requirements, it effectively reduces tracking time and unnecessary costs. About Cortellis CMC Intelligence Cortellis CMC Intelligence curates and tracks official CMC regulations and local practices for more than 135+ countries, territories and organizations for small molecules and 64 countries, territories and regions for biologics, with pre-and post-approval module coverage. Robust data is available for 25+ product and regulatory-related filters based on eCTD structure, including 6K+ source documents and over 2K links to Cortellis Regulatory Intelligence, providing access to expanded detail and in-depth summaries from experts in local regulatory practices, paired with reference source documents, to offer a complete picture. The addition of a new post-approval module now makes a comprehensive CMC solution with complete lifecycle information for drugs and biologics to increase submission rates and avoid costly delays.
お知らせ • Apr 16Clarivate Plc to Report Q1, 2024 Results on May 08, 2024Clarivate Plc announced that they will report Q1, 2024 results Pre-Market on May 08, 2024
お知らせ • Mar 13Astorg Reportedly Considers Sale of AnaquaPrivate equity firm Astorg Asset Management S A.R.L. is considering a sale of its U.S.-based intellectual property software firm Anaqua, Inc., four people familiar with the matter told Reuters, with two of them saying the company could be worth as much as $3 billion. Astorg is in the process of appointing financial advisers to gauge buyer interest in Anaqua, which offers software that manages patents, trademarks and contracts for law firms and corporations, the sources said. The process is in the early stages and Astorg is expected to proceed with an auction in the second half of the year, the people said, speaking on condition of anonymity. Astorg declined to comment. Anaqua did not immediately return requests for comment. Anaqua's competitors include French software firm QUESTEL SAS, backed by IK Partners and Eurazeo, and British-American business Clarivate Plc (NYSE:CLVT), formerly the intellectual property and science division of Thomson Reuters, according to one of the sources. Questel is among those considering a possible bid for the business, a fifth person familiar with the process said. Questel did not immediately return requests for comment. IK Partners and Eurazeo declined to comment.
お知らせ • Mar 05Clarivate Plc, Annual General Meeting, May 07, 2024Clarivate Plc, Annual General Meeting, May 07, 2024. Agenda: To consider election to the Board of Directors.
お知らせ • Feb 29+ 1 more updateClarivate plc Provides Earnings Guidance for the Fiscal Year 2024Clarivate Plc provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of $2,570 million to $2,670 million.
Reported Earnings • Feb 28Full year 2023 earnings released: US$1.47 loss per share (vs US$5.97 loss in FY 2022)Full year 2023 results: US$1.47 loss per share (improved from US$5.97 loss in FY 2022). Revenue: US$2.63b (down 1.2% from FY 2022). Net loss: US$986.6m (loss narrowed 76% from FY 2022). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 25Clarivate Plc to Report Q4, 2023 Results on Feb 27, 2024Clarivate Plc announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Feb 27, 2024
Valuation Update With 7 Day Price Move • Dec 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €8.65, the stock trades at a trailing P/E ratio of 34.3x. Average forward P/E is 16x in the Professional Services industry in Germany. Total loss to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.04 per share.
お知らせ • Dec 19Clarivate plc Announces Launch of New Special Report Series, Electrophysiology Mapping and Ablation Devices Market InsightsClarivate Plc announced the launch of a new special report series, Electrophysiology Mapping and Ablation Devices Market Insights. The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific. Findings show pulsed-field ablation (PFA) is poised to revolutionize the treatment paradigm. PFA has emerged as a breakthrough technology for the treatment of atrial fibrillation, attracting significant investment from several companies dedicated to its development. This innovative technique has produced favorable clinical outcomes compared to existing technologies and has the potential to see immediate widespread adoption following FDA approval. While both Boston Scientific and Medtronic have IDE trials for their PFA devices, Medtronic's PulseSelect PFA system received FDA approval on December 13, 2023 and Boston Scientific's FARAPULSE is expected to closely follow. There has already been a swift adoption of PFA, spurred by the approval of FARAPULSE in Europe in 2021 and its subsequent approval in Australia in 2023. This year, the global PFA market value is estimated to be $232 million with the potential to grow to $2.9 billion by the year 2028. The Electrophysiology Mappingand Ablation Devices Market Insights reports provide in-depth data and analysis of clinical practice, patient journey, and competing therapies, allowing medical device companies and physicians to make more informed and strategic decisions. The new reports highlight revised forecasts in the space for four geographies, covering: Electrophysiology Mapping & Ablation Devices - Market Insights - United States. The US EP mapping and ablation device market, which includes PFA among other technologies, is projected to experience strong growth through 2028 and is anticipated to reach a total market value of $7.2 billion by that year, driven strongly by PFA uptake. The COVID-19 pandemic had a significant impact on certain EP ablation procedures in 2020, followed by a period of recovery. Growth in market revenues will be driven by increasing ablation procedure volumes and the uptake of premium-priced devices. Innovations in this space will lead to improved outcomes and procedure growth. Electrophysiology Mapping, Ablation Devices - Market Ins insights - Asia Pacific: Although the global COVID-19 pandemic negatively impacted the Asia Pacific EP mapping and ablation devicemarket in 2020, the market has shown strong recovery and will resume pre-pandemic growth trends in the nearterm. Going forward, the Asia Pacific EP mapping and Ablation device market will expand rapidly, supported by rising AF treatment volumes, an expanding patient pool, improving access to healthcare, and the emergence of newer, premium-priced devices. Although cost constraints and a challenging reimbursement environment will hinder the pace of market expansion to some extent, the total market value is projected to reach $3.6 billion by the year 2028".
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €7.45, the stock trades at a trailing P/E ratio of 28.3x. Average forward P/E is 15x in the Professional Services industry in Europe. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.96 per share.
Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.01 loss per share (vs US$6.58 loss in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share (improved from US$6.58 loss in 3Q 2022). Revenue: US$647.2m (up 1.8% from 3Q 2022). Net loss: US$6.60m (loss narrowed 100% from 3Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 30 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 08Clarivate plc Provides Revenue Guidance for the Full Year 2023Clarivate Plc provided revenue guidance for the full year 2023. For the period,the company expects revenues to be in the range of $2.60 billion to $2.67 billion.
Breakeven Date Change • Nov 08The 10 analysts covering Clarivate previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 88% per year to 2024. The company is expected to make a profit of US$39.8m in 2025.
お知らせ • Oct 18Impactive Capital Engages in Discussions with Clarivate PlcOn October 16, 2023, Impactive Capital LP announced that it has, from time to time, engaged in, and intends to continue to engage in, discussions with members of management and the board of directors of Clarivate Plc, other shareholders, industry analysts, existing or potential strategic partners or competitors and other third parties regarding a variety of matters relating to the Company, which may include, among other things, the Company’s business, operations and expenses, strategic alternatives and direction, management, Board and management composition, environmental, social and governance considerations, and capital structure and allocation.
お知らせ • Oct 17Clarivate Plc to Report Q3, 2023 Results on Nov 07, 2023Clarivate Plc announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023
New Risk • Oct 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$4.2b Forecast net loss in 2 years: US$9.2m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.4% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$9.2m net loss in 2 years).
New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Sep 27Clarivate Plc (NYSE:CLVT) acquired Alethea.Clarivate Plc (NYSE:CLVT) acquired Alethea on September 26, 2023. Eran Segal, co-founder and CEO of Pangea and his team will join Clarivate.Clarivate Plc (NYSE:CLVT) completed the acquisition of Alethea on September 26, 2023.
お知らせ • Sep 26Clarivate Plc Establishes Academia & Government Innovation IncubatorClarivate Plc announced it has established an Academia & Government Innovation Incubator. This will further accelerate its strategy to drive innovation, utilize artificial intelligence and introduce novel solutions for its academic users and customers. The Incubator's first program focuses on realizing better learning outcomes and student success through the acquisition of Alethea, an AI-powered students' content engagement platform created by Pangea. Alethea facilitates meaningful engagement with academic texts, class readings, and assignments through personalized and adaptive guidance. It provides faculty and librarians with the insights they need to analyze students' reading engagement and rapidly adapt their teaching.
New Risk • Aug 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Breakeven Date Change • Aug 04Forecast breakeven date pushed back to 2024The 8 analysts covering Clarivate previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 100% to 2023. The company is expected to make a profit of US$6.64m in 2024. Average annual earnings growth of 171% is required to achieve expected profit on schedule.
お知らせ • Aug 04+ 1 more updateClarivate plc Updates Earnings Guidance for the Year 2023Clarivate Plc updated earnings guidance for the year 2023. For the year, the company expects revenue to be $2.60 Billion to $2.67 Billion compared to previous guidance of $2.63 Billion to $2.73 Billion.
Reported Earnings • Aug 03Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.065 profit in 2Q 2022)Second quarter 2023 results: US$0.21 loss per share (down from US$0.065 profit in 2Q 2022). Revenue: US$668.8m (down 2.6% from 2Q 2022). Net loss: US$141.7m (down 424% from profit in 2Q 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 08Clarivate Plc to Report Q2, 2023 Results on Aug 03, 2023Clarivate Plc announced that they will report Q2, 2023 results at 9:30 AM, US Eastern Standard Time on Aug 03, 2023
お知らせ • Jun 28Clarivate Plc, Annual General Meeting, Jul 27, 2023Clarivate Plc, Annual General Meeting, Jul 27, 2023, at 08:00 Eastern Daylight. Location: THE GROVE, Chandler’s Cross, Hertfordshire, WD3 4TG Heretfordshire United Kingdom Agenda: To approve repurchase of ordinary shares in open-market transactions on the terms described in further detail herein (the Open-Market Share Repurchase Proposal"); and to transact such other business as may properly come before the General Meeting.
お知らせ • May 13Clarivate Plc Elects Saurabh Saha as DirectorClarivate Plc held its 2023 Annual General Meeting of Shareholders on May 4, 2023, elected Saurabh Saha as director.
Breakeven Date Change • May 10Forecast breakeven date moved forward to 2023The 9 analysts covering Clarivate previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$49.6m in 2023. Earnings growth of 107% is required to achieve expected profit on schedule.
お知らせ • May 10Clarivate plc Provides Earnings Guidance for the Year 2023Clarivate Plc provided earnings guidance for the year 2023. For the year, the company expects revenues in the range of $2.63 billion to $2.73 billion, Organic Revenue Growth in the range of 2.75% to 3.75%.
Reported Earnings • May 09First quarter 2023 earnings released: EPS: US$0.037 (vs US$0.074 in 1Q 2022)First quarter 2023 results: EPS: US$0.037 (down from US$0.074 in 1Q 2022). Revenue: US$629.1m (down 5.0% from 1Q 2022). Net income: US$24.7m (down 51% from 1Q 2022). Profit margin: 3.9% (down from 7.7% in 1Q 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
Breakeven Date Change • Mar 02No longer forecast to breakevenThe 7 analysts covering Clarivate no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$90.4m in 2024. New consensus forecast suggests the company will make a loss of US$65.5m in 2024.
お知らせ • Feb 08Clarivate Plc to Report Q4, 2022 Results on Mar 01, 2023Clarivate Plc announced that they will report Q4, 2022 results Pre-Market on Mar 01, 2023
Recent Insider Transactions • Nov 18Chief Product Officer recently sold €1.0m worth of stockOn the 15th of November, Gordon Samson sold around 100k shares on-market at roughly €10.09 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.4m more than they bought in the last 12 months.
Breakeven Date Change • Nov 16Forecast breakeven date pushed back to 2024The 8 analysts covering Clarivate previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 49% per year to 2023. The company is expected to make a profit of US$113.6m in 2024. Average annual earnings growth of 121% is required to achieve expected profit on schedule.